WELL Health
Trending >

CannTrust Holdings has a 57 per cent upside, GMP says

CannTrust Holdings

CannTrust HoldingsWith a new infusion of cash and EBITDA-positive status, licensed cannabis producer CannTrust Holdings Inc. (CannTrust Holdings Stock Quote, Chart, News: TSX:TRST) is a “Buy,” says analyst Martin Landry with GMP Securities.

In a Thursday coverage resumption, Landry dropped his target for TRST to $14.50.

Yesterday, Vaughan, Ontario-based CannTrust announced the closing of a $100 million bought deal with Canaccord Genuity and GMP Securities co-leading the underwriting. The company says it will use about $17 million of the proceeds to build a 485,000 sq. ft. greenhouse in Niagara, Ontario, about $14 million on new extraction equipment and infrastructure, $10 million on global investments and a further $25 million on branding, new products, distribution and corporate use.

Landry says that CannTrust’s crop yields, currently at over 300 grams per sq. ft., are among the highest in the sector, which lead to it being one of only four public growers to generate positive EBITDA over the past 12 months.

At the same time, CannTrust’s first quarter 2018 financials came in slightly under expectation, with revenue of $7.8 million (versus the consensus $7.9 million) and an EBITDA loss of $1.4 million (versus the consensus negative $0.2 million).

“With a cash balance in excess of $100m, CannTrust is well funded to carry its near-term expansion plans and bring production capacity in excess of 100 tonnes,” says Landry. “However, the last two quarters have come below expectations on lower selling prices and higher production costs. We reduce our forecasts to reflect lower pricing and higher SG&A spend in anticipation of the rec market.”

Landry’s 2018 estimates have CannTrust producing revenue of $82.0 million (was $88.2 million) and EBITDA of $9.8 million (was $26.0 million). His 2019 estimates call for a topline of $219.1 million (was $241.4 million) and EBITDA of $63.1 million (was $78.1 million).

The analyst’s target price of $14.50 (was $16.00) represents a projected return of 57 per cent at the time of publication.

Disclosure: Jayson MacLean owns shares of CannTrust Holdings.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook


Leave a Reply